In Vivo Targeting of T-Cells with Antibody- and Cytokine Conjugated Liposomes
Invention type: Technology
/
Case number: #16405H
The invention provides compositions and methods for, inter alia, augmenting cell-based therapies in vivo by repeatedly stimulating target cells of interest over a period of time.
Researchers
Yiran Zheng
/
Yuan Zhang
/
Brandon Kwong
/
Darrell J Irvine
Departments: David H Koch Institute for Integrative Cancer Res
Technology Areas: Biotechnology: Cell Separation, Sensors & Monitoring / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living
-
in vivo targeting of cells with ligand-conjugated particles
European Patent Convention | Granted | 3,010,528 -
in vivo targeting of t-cells with ligand-conjugated particles
Canada | Published application -
in vivo targeting of cells with ligand-conjugated particles
Switzerland | Granted | 3,010,528 -
in vivo targeting of cells with ligand-conjugated particles
Germany | Granted | 3,010,528 -
in vivo targeting of cells with ligand-conjugated particles
France | Granted | 3,010,528 -
in vivo targeting of cells with ligand-conjugated particles
United Kingdom | Granted | 3,010,528 -
in vivo targeting of cells with ligand-conjugated particles
Italy | Granted | 3,010,528 -
in vivo targeting of cells with ligand-conjugated particles
Netherlands | Granted | 3,010,528 -
in vivo targeting of cells with ligand-conjugated particles
Sweden | Granted | 3,010,528 -
in vivo targeting of cells with ligand-conjugated particles
United States of America | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.